reason report
bottom line translat morn report first clinic
data inhal mrna treatment cystic fibrosi nine
patient treat one three differ singl dose
four patient experienc substanti clinic benefit
singl dose magnitud benefit
impress mean best dose group
improv investor concern
variabl respons patient treat higher two
dose signific benefit invers dose
respons patient respond dose wherea
respond highest dose investor also
concern unusu time curv respons
respons seen appear peak day declin
day consist compani expect
current advanc develop
market late blend probabl success
probabl seem appropri given stage result
basi maintain outperform rate price target
move updat quarterli result
see releas concurr data show data
patient significantli patient
follow-up highest prioriti confirm
effect durabl repeat dose confirm
clinic effect inde mediat mrna rather
inhal vehicl surprisingli earli onset effect day
associ febril reaction could consist reaction
lnp formul rather effect mrna
investor expect singl ascend dose sad trial
low lack dose respons transient fever
highest dose may add caution believ produc
larg enough lung function benefit attribut effect intervent
mrna vehicl instead random specif two patient
maximum absolut increas lung function
mid high dose respect also demonstr benefit
patient current applic vertex
mp drug fast market opportun translat
expect stock mute favor reaction
data due nois within trial anticip signific interest
build multipl dose data releas
compani inform svb leerink llc research
revenu mm non-gaap ep
dcf wacc
termin growth rate
net debt total capit
year price history/av daili volume mil
pleas refer page import disclosur price chart analyst certif
translat also report earn signific updat
compani spent quarter oper expens
oper cash outflow adjust model
current cash posit share count updat
expens estim quarter updat price target
reiter outperform rate
earli stage biotechnolog compani develop mrna-bas therapeut
platform treat cystic fibrosi compani aspir use platform develop vaccin
treat rare diseas over-the-counter defici lead product
offer opportun treat patient class cystic fibrosi transmembran conduct
regul cftr mutat cystic fibrosi patient synthes full length
cftr protein design deliv mrna lung epitheli cell result
product function cftr protein cystic fibrosi market like domin
mp forese futur current treatment option avail cf patient
class cftr mutat provid signific commerci opportun
patient popul phase i/ii trial posit anticip phase trial start
possibl fda approv base potenti increment benefit
cf popul also assum modest penetr cystic fibrosi patient non-
class mutat forecast oper loss least believ
treatment revenu potenti success
data collect singl ascend dose sad portion mrna therapeut
encod fulli function cystic fibrosi transmembran conduct regul cftr protein
deliv lung cell nebul proprietari lipid nanoparticl lnp translat enrol
adult patient cf sad portion eleven patient mutat seven
took approv cftr modul screen dose follow-up translat
requir patient stabl cftr modul dose least day
screen remain four cftr modul final patient
mutat amend cftr modul patient assign evenli placebo
dose group safeti measur day lung function
measur percent predict forc expiratori volum one second assess
baselin day
lung function improv observ two highest dose dose respons
baselin balanc across arm measur
placebo respect translat report
maximum absolut chang baselin day placebo
max lung function chang
maximum chang higher placebo show
dose respons relationship best dose individu absolut lung function
increas two patient alreadi stabl cftr
modul importantli one patient mutat
address vertex cftr modul day last day lung function measur
mean absolut chang baselin placebo day mean lung
function chang
safeti issu emerg highest dose day treatment-emerg
seriou advers event sae howev five patient includ three dose
cohort experienc transient post-dos febril reaction deem relat studi drug
patient fever-lik symptom includ headach fatigu chill nausea resolv
hour routin fever treatment ae appear reaction therapi
translat report five patient low level mrna detect blood
suggest mrna could bypass mucu layer lung nebul mrna
deliveri poc translat also report two pulmonari exacerb highest
dose cohort higher incid moder grade compar
placebo
propos trial amend respons lack dose respons translat propos
protocol chang subsequ portion phase i/ii trial first compani
enrol sad cohort on-going multipl ascend dose mad portion
test weekli dose translat add effect sad dose cohort
four patient cancel mad arm cancel arm
justifi clear fever signal lack increas benefit measur system exposur
mrna ideal nebul local therapi chang yet
approv fda translat guid share data addit sad cohort
on-going mad portion trial translat also plan unveil detail data
today top-lin releas north american cystic fibrosi confer nacfc held
octob novemb
svb leerink estim unchang continu model launch
risk-adjust revenu reach peak also continu
model higher probabl success patient address
price target base dcf methodolog cash flow
assign termin valu forecast sale cystic
fibrosi begin grow total blend probabl
success assum discount rate given earli stage compani
longer term valu stock could significantli appreci
result on-going anticip trial increas probabl success
assign develop lead compound
earli stage compani disclos littl inform mrna
construct lipid nanoparticl lnp deliveri system henc investor subject
typic risk associ clinic stage biotechnolog compani also risk associ
lack valid overal technolog mrna compar therapeut
approach mrna medicin develop therapeut approach mani
year medicin come market yet tbio lead program face technolog
risk usual develop risk earli stage target biopharmaceut program
also face risk associ competit develop categori mrna platform
cf treatment approach industry-wid risk includ advers regulatori
reimburs polit develop final like earli stage biopharmaceut
compani tbio capit risk like larg investor anticip signific
dilut financ activ prior reach profit forecast
million
svb leerink llc compani report
million
sale
chang fair valu conting consider
svb leerink llc compani report
brand
type event
event trial detail
date known
up/down
expect
cohort phase i/ii sad/mad
svb leerink llc equiti research compani file
complet addit preclin studi
submit data studi fda
enterpris valu termin valu
million except ep
discount period year eoy indic
discount factor
incur yet
termin valu discount year today mm
annual flow disc year today mm
total present valu flow tv discount mm
enterpris value-per-share year today
year today mm
cash-per-share year today
equiti valu year today
svb leerink llc compani report
